DDInter1100 DDInter905
Lubiprostone is a medication used in the management of idiopathic chronic constipation. A prostaglandin E1 derivative, lubiprostone is a bicyclic fatty acid that activates ClC-2 chloride channels located on the apical side of the gastrointestinal epithelial cells. Activation of these channels promotes the secretion of a chloride-rich fluid that soften the stool, increase gastrointestinal motility, and induce spontaneous bowel movements (SBM).
Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with rituximab in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities, while in the treatment of FL and SLL it is intended to be used in patients who have received at least two prior systemic therapies. More specifically, idelalisib targets P110δ, the delta isoform of the enzyme phosphatidylinositol-4,5-bisphosphate 3-kinase, also known as PI-3K. The PI-3Ks are a family of enzymes involved in cellular functions such as cell growth, proliferation, differentiation, motility, survival and intracellular trafficking, which in turn are involved in cancer. In contrast to the other class IA PI3Ks p110α and p110β, p110δ is principally expressed in leukocytes (white blood cells) and is important for the function of T cells, B cell, mast cells and neutrophils. By inhibiting this enzyme, idelalisib induces apoptosis of malignant cells and inhibits several cell signaling pathways, including B-cell receptor (BCR) signaling and C-X-C chemokine receptors type 5 and type 4 signalling, which are involved in trafficking and homing of B-cells to the lymph nodes and bone marrow. Treatment of lymphoma cells with idelalisib has been shown to result in inhibition of chemotaxis and adhesion, and reduced cell viability.
Lubiprostone {u} (Compound) binds {v} (Gene) CBR1
CBR1 {u} (Gene) is bound by {v} (Compound) Haloperidol
Haloperidol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Idelalisib
Lubiprostone {u} (Compound) causes {v} (Side Effect) Anorexia
Anorexia {u} (Side Effect) is caused by {v} (Compound) Zidovudine
Zidovudine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Idelalisib
Lubiprostone {u} (Compound) binds {v} (Gene) CBR1
CBR1 {u} (Gene) is upregulated by {v} (Compound) Tiagabine
Tiagabine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Idelalisib
Lubiprostone {u} (Compound) causes {v} (Side Effect) Anorexia
Anorexia {u} (Side Effect) is caused by {v} (Compound) Sibutramine
Sibutramine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Idelalisib
Lubiprostone {u} (Compound) binds {v} (Gene) CBR1
CBR1 {u} (Gene) is downregulated by {v} (Compound) Omacetaxine mepesuccinate
Omacetaxine mepesuccinate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Idelalisib
Lubiprostone {u} (Compound) causes {v} (Side Effect) Connective tissue disorder
Connective tissue disorder {u} (Side Effect) is caused by {v} (Compound) Deferiprone
Deferiprone {u} may lead to a major life threatening interaction when taken with {v} Idelalisib
Lubiprostone (Compound) binds CBR1 (Gene) and CBR1 (Gene) is bound by Haloperidol (Compound) and Haloperidol may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Lubiprostone (Compound) causes Anorexia (Side Effect) and Anorexia (Side Effect) is caused by Zidovudine (Compound) and Zidovudine may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Lubiprostone (Compound) binds CBR1 (Gene) and CBR1 (Gene) is upregulated by Tiagabine (Compound) and Tiagabine may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Lubiprostone (Compound) causes Anorexia (Side Effect) and Anorexia (Side Effect) is caused by Sibutramine (Compound) and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Idelalisib
Lubiprostone (Compound) binds CBR1 (Gene) and CBR1 (Gene) is downregulated by Omacetaxine mepesuccinate (Compound) and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Lubiprostone (Compound) causes Connective tissue disorder (Side Effect) and Connective tissue disorder (Side Effect) is caused by Deferiprone (Compound) and Deferiprone may lead to a major life threatening interaction when taken with Idelalisib